Visualitzant l d'Hebron Institut d'Oncologia

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Tempero, Margaret A.; Tabernero Caturla, Josep; Reni, Michele; Van Cutsem, Eric; Hendifar, Andrew E.; Macarulla Mercadé, Teresa; Oh, Do-Youn (Elsevier, 2021-05)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Giné Soca, Eva; de la Cruz, Fatima; Jimenez-Ubieto, Ana; Terol, M. Jose; Marin Niebla, Ana; Martín García-Sancho, Alejandro; Lopez-Jimenez, Javier (American Society of Clinical Oncology, 2022-04-10)

ICO-ICS Praxi per al tractament mèdic del càncer epitelial d'ovari

Barretina-Ginesta, Maria-Pilar; Guerra-Prió, Silvia; Lezcano-Rubio, Clara; Mangues-Bafalluy, Irene; Pardo, Beatriz; Piulats, Josep M.; Oaknin Benzaquen, Ana Mazaltob; Recalde-Penabad, Sabela; Romeo-Marín, Marga; Rey-Salido, Montserrat; Carreras Soler, Maria Josep; Gil Martín, Marta (Institut Català de la SalutInstitut Català d'Oncologia, 2017-11)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Serra Elizalde, Violeta; Wang, Anderson T.; Castroviejo Bermejo, Marta; Polanska, Urszula M.; Palafox Sánchez, Marta; Llop Guevara, Alba; Guzman Torres, Marta; Rodriguez Ferreiro, Olga; Grueso Gragera, Judit; Arribas López, Joaquin Vicente; Cortés Castan, Javier; Cruz Zambrano, Cristina; Balmaña Gelpí, Judith; Saura Manich, Cristina; Herencia Ropero, Andrea (American Association for Cancer Research, 2022-10-15)

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Tian, Tian V; Vidal, Enrique; Graf, Thomas; Stik, Grégoire (MyJove Corporation, 2020-04-29)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Jiménez-Labaig, P.; Pacheco-Barcia, V.; Cebrià, A.; Gálvez, F.; Obispo, B.; Páez, David; Felip Font, Enriqueta; Elez Fernandez, Mª Elena; Bosch-Barrera, Joaquim (Elsevier, 2021-08)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Blumenberg, Viktoria; Iacoboni García-Calvo, Gloria; Kharboutli, Soraya; Hernani, Rafael; Barba Suñol, Pere; Lopez Corral, Lucia; Rejeski, Kai (Wolters Kluwer Health, 2023-04)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Lheureux, Stephanie; Prokopec, Stephenie; Oldfield, Leslie E.; Gonzalez-Ochoa, Eduardo; Bruce, Jeff; Wong, Derek; OAKNIN, ANA (American Association for Cancer Research, 2023-09-15)

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Ernst, Matthew; Yuasa, Takeshi; Takemura, Kosuke; Suárez Rodríguez, Cristina; Navani, Vishal; Wells, Connor; Donskov, Frede (American Medical Association, 2022-06-01)

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Rubio Pérez, Carlota; Planas Rigol, Ester; Trincado, Juan L.; Bonfill Teixidor, Ester; Arias Piñeiro, Alexandra; Marchese, Domenica; Iurlaro, Raffaella; Martínez Ricarte, Francisco Ramón; Escudero Monreal, Laura; Cordero Asanza, Esteban Xavier; Cicuendez López Ocaña, Marta; Nuciforo, Paolo Giovanni; Sahuquillo Barris, Joan; Tabernero Caturla, Josep; Seoane Suarez, Joan; Serna, Garazi (Nature Research, 2021-03-08)

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Auclin, Edouard; Zubiri, Leyre; sophie, schneider; Minatta, Jose Nicolas; REMON, JORDI; Rodriguez-Abreu, Delvys; MUÑOZ COUSELO, EVA (Elsevier, 2024-04-22)

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Cortellini, Alessio; Dettorre, Gino M; Dafni, U.; Aguilar Company, Juan; Castelo-Branco, L.; Lambertini, Matteo (BMJ, 2022-11)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Griguolo, Gaia; Pascual, Tomás; Fasani, Roberta; Chic, N.; Antunes de Melo Oliveira, Ana Mafalda; Nuciforo, Paolo Giovanni; Serna, Garazi; Guardia, Xavier (Nature Research, 2021-03-19)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Quintela-Fandino, Miguel; Holgado, Esther; Manso, Luis; Bermejo, Begoña; Colomer, Ramon; Cortés Castan, Javier; Morales, Serafin (BMC, 2020-11-11)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Jiménez Bernal, Isabel; Tazón Vega, Bárbara; Abrisqueta Costa, Pablo; Nieto Sáchica, Juan Camilo; Bobillo Varela, Sabela; Palacio García, Carlos; Carabia Juberó, Júlia; Munuera Codina, Magdalena; Puigdefabregas Horta, Lluis; Franco Jarava, Clara; Iacoboni García-Calvo, Gloria; Crespo Maull, Marta; Bosch Albareda, Francesc (BMC, 2021-05-20)

Immunotherapies against HER2-Positive Breast Cancer

Duro Sánchez, Santiago; Román Alonso, Macarena; Arribas López, Joaquin Vicente (MDPI, 2023-02-08)

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers

Ros, Javier; Baraibar, Iosune; Saoudi Gonzalez, Nadia; R Castells, Marta; Salvà, Francesc; Tabernero, Josep; Elez, Elena (MDPI, 2023-08-24)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Tarantino, Paolo; Corti, Chiara; Cortés Castan, Javier; Mittendorf, Elizabeth; Schmid, Peter; Rugo, Hope (Nature Research, 2022-02-18)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer

Elez Fernandez, Mª Elena; Chianese, Chiara; Matito Ariza, Judit; Macarulla Mercadé, Teresa; Argilés Martinez, Guillem; Garcia Rodriguez, Ariadna; Mulet Margalef, Núria; Tabernero Caturla, Josep; Vivancos Prellezo, Ana; Sanz Garcia, Enrique; Martinelli, Erica; Noguerido Castro, Alba; Mancuso, Francesco Mattia; Caratù, Ginevra; Grasselli, Julieta; Martini, Giulia; Capdevila Castillon, Jaume (FEBS Press, 2019-07-31)

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

García Fortes, María; Alvarez-Larran, Alberto; Raya, José M.; Angona, Anna; Estrada, Natalia; Fox, Maria Laura; Hernandez-Boluda, Juan Carlos (MDPI, 2022-05)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant Vall d'Hebron Institut d'Oncologia - VHIO per títol

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

ICO-ICS Praxi per al tractament mèdic del càncer epitelial d'ovari

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Immunotherapies against HER2-Positive Breast Cancer

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant Vall d'Hebron Institut d'Oncologia - VHIO per títol

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study ﻿

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial ﻿

ICO-ICS Praxi per al tractament mèdic del càncer epitelial d'ovari ﻿

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance ﻿

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C) ﻿

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM) ﻿

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL ﻿

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression ﻿

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma ﻿

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment ﻿

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort ﻿

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries ﻿

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer ﻿

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial ﻿

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia ﻿

Immunotherapies against HER2-Positive Breast Cancer ﻿

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers ﻿

Immunotherapy for early triple negative breast cancer: research agenda for the next decade ﻿

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer ﻿

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

ICO-ICS Praxi per al tractament mèdic del càncer epitelial d'ovari

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Identification of Enhancer-Promoter Contacts in Embryoid Bodies by Quantitative Chromosome Conformation Capture (4C)

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Immunotherapies against HER2-Positive Breast Cancer

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis